Recombinant Virus Influenza A nucleoprotein Protein

Product Discontinued

Recombinant Virus Influenza A nucleoprotein Protein Summary

• Preparation Method: A cDNA coding for Human Influenza-A (Influenza A virus (A/Puerto Rico/8/34/Mount Sinai (H1N1)) segment 5) nuclear protein NP was cloned into a Baculovirus expression vector. The recombinant HNP-A was purified by proprietary chromatographic techniques.
• Protein/Peptide Type: Recombinant Protein
• Purity: Chromatography

Applications/Dilutions

• Dilutions:
  • Dot Blot
  • ELISA
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
  • SDS-Page 2-10 ug/lane
• Application Notes: Use in DB reported in scientific literature (PMID:33348840). This protein migrates as a 55 kDa band in SDS-PAGE. Use in Immunohistochemistry-Paraffin reported in scientific literature (PMID 24657788). The protein concentration was estimated in a BioRad assay. The absolute purity of the recombinant protein preparation has not been established.
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: 20 mM HEPES, pH7.0, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT.
• Preservative: No Preservative
• Concentration: 1 mg/ml
• Purity: Chromatography

Notes

For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Alternate Names for Recombinant Virus Influenza A nucleoprotein Protein

• Influenza A virus NP
• NP
• NP-A
• Nucleocapsid protein
• Nucleoprotein

Background

This protein migrates as a 55 kDa band in SDS-PAGE.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Publications for Influenza A nucleoprotein Recombinant Protein (NBP2-24986)(24)

Publications using NBP2-24986

• Michelini Z, Minkoff JM, Yang J et al. Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza Viruses 2020-12-17 [PMID: 33348840] (Cytometric Bead Assay Standard)
• Singh S, Nehete PN, Yang G et al. Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant. Vaccines. 2014-10-10 [PMID: 25553254] (In Vivo, In vitro)
  
  Details:
  Influenza A nucleoprotein Protein (NP) used for in vitro and in vivo experiments involving Rhesus Macaques / Monkeys model.
• Panyasing Y, Goodell C, Kittawornrat A et al. Influenza A Virus Surveillance Based on Pre-Weaning Piglet Oral Fluid Samples. Transbound Emerg Dis. 2014-12-09 [PMID: 25488821]
• He XS, Holmes TH, Sanyal M et al. Distinct patterns of B-cell activation and priming by natural influenza infection versus inactivated influenza vaccination. J. Infect. Dis. 2014-10-21 [PMID: 25336731] (In-vitro)
• Yeo Sj, Huong Dt, Hong Nn et al. Rapid and Quantitative Detection of Zoonotic Influenza A Virus Infection Utilizing Coumarin-derived dendrimer-based Fluorescent Immunochromatographic Strip Test (FICT). Theranostics. 2014-10-06 [PMID: 25285172]
• Luetkens T, Kobold S, Cao Y et al. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol Immunother. 2014-07-31 [PMID: 25078248]
• Fontana JM, Christos PJ, Michelini Z et al. Mucosal Immunization with Integrase-Defective Lentiviral Vectors Protects against Influenza Virus Challenge in Mice. PLoS ONE. 2014-05-14 [PMID: 24824623] (ELISA, Mouse)
  
  Details:
  ELISA: Mouse serum from mice innoculated with IDLV-NP (lentiviral vector expression the influenza virus nucleoprotein), Figs 4, 5. The Influenza A recombinant nucleoprotein was used for an NP-specific serum IgG ELISA. 96-well microplates were coated with
• Sasaki S, Holmes TH, Albrecht RA et al. Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J. Infect. Dis. 2014-03-27 [PMID: 24676204] (ELISA, Human)
  
  Details:
  Fig 7A, ELISPOT plates were coated with the recombinant influenza A virus nuclear protein at 4.5 ug/ml.
• Kwon D, Shin K, Kim SJ et al. Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea. Virus Res. 2014-03-19 [PMID: 24657788] (IHC-P)
• Panyasing Y, Goodell CK, Gimenez-Lirola L et al. Kinetics of influenza A virus nucleoprotein antibody (IgM, IgA, and IgG) in serum and oral fluid specimens from pigs infected under experimental conditions. Vaccine 2013-12-16 [PMID: 24200976] (ELISA)
• Lin Feng, Shen Xuefei, Kichaev Gleb et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods. 2012-06-01 [PMID: 22794496] (ELISA, Mouse)
• Shriner Susan A, VanDalen Kaci K, Mooers Nicole L et al. Low-pathogenic avian influenza viruses in wild house mice. PLoS One. 2012-01-01 [PMID: 22720076] (ELISA)
• Shen X, S0derholm J, Lin F et al. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine. 2012-11-06 [PMID: 22406460]
  
  Details:
  ELISA: The IMR-274 NP-A recombinant protein was used to detect antibody responses in the serum of mice immunized with plasmids encoding NP two weeks following the last immunization (Fig 3a). NP-A (IMR-274) was coated onto a Nunc Maxi-Sorp Immuno Plate at
• Buriani G, Mancini C, Benvenuto E, Baschieri S. Heat-shock protein 70 from plant biofactories of recombinant antigens activate multiepitope-targeted immune responses. Plant Biotechnol J. 2012-04-01 [PMID: 22221920]
  
  Details:
  Products cited for ELISA in plants and mice: 1. Recombinant Influenza A Nucleoprotein (NP-A, IMR-274), Protein standard (Fig 1A) and ELISA capture (Fig 6) 2. Influenza A/NP-1 mAb, clone 2F205 (IMX-5214), Detection antibody (Fig 1A) Notes: Fig 1A: Leaf ext
• Quinn K, Quirion MR, Lo CY et al. Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response. Mol Ther. 2011-11-01 [PMID: 21829176]
  
  Details:
  ELISA: Detection of antibody responses to NP-A after virus vaccination in mice (Fig 5). NP-A (IMR-274) was coated onto ELISA plates at 1 ug/ml in PBS buffer, blocked for 2 h with 1% FBS in PBS and the incubated with fourfold serially diluted serum (1/20-1
• Soboleski MR, Gabbard JD, Price GE et al. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One. 2011-01-01 [PMID: 21789196]
  
  Details:
  ELISA: Detection of antibody responses to NP-A in the serum of immunized in mice at various time points following virus immunization (Fig 1). NP-A (IMR-274) was coated onto ELISA plates at 1 ug/ml in 0.125 saline, 0.007 M borate buffer overnight. at 4 deg
• Broderick Kate E, Kardos Thomas, McCoy Jay R et al. Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity. Hum Vaccin. 2011-01-01 [PMID: 21263230] (ELISA, Bovine)
• Jelinek I, Leonard JN, Price GE et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol. 2011-02-15 [PMID: 21242525]
  
  Details:
  Immunization (Fig 7): Mice were immunized with 20 ug NP-A (IMR-274) alone or in combination with either dsRNA oligonucleotides (10 ug) or polyinosinic:polycytidylic acid (10 ug) in the rear quadricepts, 7-10 mice/group. Four weeks post immunization, the animal groups were boosted using the same protocol. Three weeks after boosting, the mice were challenged with influenza virus and monitored for survival.
• Lin F, Shen X, McCoy JR et al. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine. 2011-09-09 [PMID: 21199706]
• Blitvich BJ, Ibarra-Juarez LA, Cortes-Guzman AJ et al. Seroprevalence of equine influenza virus in north-east and southern Mexico. Vet Rec. 2010-05-01 [PMID: 20435984] (Human)
  
  Details:
  ELISA, the IMR-274 recombinant protein was used in ELISA to evaluate antibodies to influenza virus sub-types in human serum samples. Data described but not shown.
• Rao SS, Kong WP, Wei CJ et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One. 2010-03-23 [PMID: 20352112]
  
  Details:
  ELISA: Detection of humoral immune responses to NP after DNA vaccination in mice (Fig 2) or ferrets (Fig 4). The recombinant Influenza A nucleoprotein (NP-A) IMR-274 was used to coat ELISA plates.
• Price GE, Soboleski MR, Lo CY et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine. 2009-11-05 [PMID: 19729082]
  
  Details:
  ELISA (Fig 1): Detection of immune responses to NP after influenza A plasmid immunization in mice. NP-A (IMR-274) was used to coat ELISA plates. Antibody levels were measured in serum, nasal wash and brochoalveolar lavage. Data was expressed as endpoint titers defined as the highest dilution of sample giving an OD 405 nm reader greater than three SD above the mean of naive samples.
• Sullivan HJ, Blitvich BJ, VanDalen K et al. Evaluation of an epitope-blocking enzyme-linked immunosorbent assay for the detection of antibodies to influenza A virus in domestic and wild avian and mammalian species. J Virol Methods. 2009-10-01 [PMID: 19523985]
  
  Details:
  Epitope-blocking ELISA (bELISA): Tables 1, 2 Fig 1, Detection of antibodies to influenza A virus in taxonomically diverse domestic and wild vertebrate species, and mammalian species. The assay was first developed using raccoon and mallard serum. Serum from both naturally exposed and influenza A virus experimentally challenged animals was evaluated. Then sera from 215 birds and 38 mammals was used for further bELISA studies. For the bELISA studies, wells of 96-well ELISA plates were each coated 100 ul (143 mg/ml) of NP-A (IMR-274) in carbonate-bicarbonate buffer (50 mM sodium carbonate, 50 mM sodium bacarbonate, pH 9.6) and incubated overnight at 4 degrees C. See publication for additional assay details.
• Nichols JE, Cortiella J, Lee J et al. In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. Biomaterials. 2009-02-01 [PMID: 19042018]
  
  Details:
  Products cited for ELISA (Fig 3J): 1. Recombinant Influenza A Nucleoprotein (A/NP-A: IMR-274), Protein Standard 2. Influenza A/NP-A pAb (IMX-5214), Capture antibody 3. Influenza A/NP-A mAb (IMG-5134A), Detection antibody